SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid fears of supply disruptions from Middle East shipping and energy-infrastructure attacks, with traders also watching Ukrainian strikes on Russian oil assets. Bulls cite the supply risks, while bears argue the rally is stretched and could reverse if diplomacy or eased Russian sanctions restores supply; higher oil is also fueling inflation concerns and pressure on broader markets.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO slide to fresh lows is drawing attention, with traders citing share-unlock overhang and insider selling, alongside a TD Cowen price-target cut and concerns about OpenAI customer concentration and competition from Nvidia. The community is split between buyers calling the stock oversold and bears expecting further pressure until lockup expirations pass and the company demonstrates growth and scaling.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is centered on concerns about its debt-heavy expansion and costly financing, with HSBCs bearish assessment adding to worries that AI demand may not translate into adequate returns. Traders are split between viewing the backlog and ongoing AI demand as a buying opportunity and fearing that credit costs and refinancing needs could constrain growth; a Goldman upgrade has not settled the debate.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock to Sell, citing long commercialization timelines and a lack of firm customer commitments, amid questions about delays to the proposed TVA deployment. Traders are split between viewing the selloff as an overreaction to the rating and seeing it as a warning about execution risk and the companys ability to turn its reactor technology into binding projects.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors Q3 results are driving attention: traders cite strong revenue growth and margins but debate the GAAP EPS miss and the absence of forward guidance, with many waiting for the earnings-call outlook to assess the report and valuation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the AI-linked selloff has QQQ traders debating whether the move is a lasting recovery or a brief relief rally, with upcoming megacap earnings seen as a test. Concerns about AI infrastructure spending and credit risks, alongside surging oil and inflation worries, are keeping sentiment volatile.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops reminder that its warrants will expire unexercised if holders miss the deadline has become the main focus, with the share price below the exercise threshold. Traders disagree over whether the warrants will lapse and remove a potential dilution overhang or whether Ryan Cohen will take action to make them valuable; some warrant holders express frustration while bulls point to his recent share purchases.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp AI-infrastructure selloff, as traders debate neocloud funding risks and Gartners warning that many providers may face consolidation. The community is split between viewing the recent bounce as an oversold relief move and expecting further weakness; bulls argue Nebius may be better positioned than debt-heavy peers and could benefit if demand shifts.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs Q3 earnings beat and stronger cash-flow outlook, alongside a new share-repurchase authorization, are driving discussion. Traders are weighing those positives against the stocks decline, pointing to a narrowed but unchanged-midpoint profit outlook and softer U.S. sales as reasons the beat did not spark a stronger reaction.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after reporting a strong third-quarter earnings beat and raising its full-year sales, earnings, and cash-flow outlook, with strength across its aerospace and defense businesses. Traders are broadly positive, though some question how much of the guidance increase reflects IEEPA cost recovery versus underlying growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaso Stock Surges 149% in a Year: What's Behind the Rally?

VASO is gaining from higher equipment deliveries, growing deferred commissions and a sharper healthcare focus, though partner dependence and margin pressures persist.

Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow

GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a large multisite academic health system in Anesthesia & Analgesia Practice. The retrospective observational study analyzed...

ISRG Ahead of Q3 Earnings: Can Procedure Growth Sustain Momentum?

Intuitive Surgical's Q3 earnings hinge on robotic surgery growth, system demand and margins amid slowing US procedures, China headwinds and premium valuation.

GE HealthCare's MINItrace Magni achieves CE Mark; Copper-64 expands PETtrace Solid Target Platform beyond Gallium-68

GE HealthCare (Nasdaq: GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 (Cu) production. Together, the developments reflect the companys focus on helping institutions...

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

Equity

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 


GE HealthCare to announce third quarter 2026 results on October 28, 2026

GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will...

GE HealthCare Expands U.S. PET Radiopharma Reach With SOFIE Deal

GEHC's $945M SOFIE Biosciences deal will expand its U.S. PET radiopharmaceutical footprint and boost exposure to precision care growth.

GE HealthCare To Acquire SOFIE Biosciences For $945M — Here’s What GEHC Investors Need To Know

GE HealthCare is adding SOFIE’s PET radiopharmaceutical manufacturing footprint and U.S. rights to FAPI-74 as it expands its presence in precision diagnostics.


Here's How Tempus AI is Capitalizing on AI-ECG Market Growth

TEM is expanding its cardiovascular portfolio with FDA-cleared AI-ECG tools targeting complex cardiac conditions.

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027...

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment provides scanning devices, clinical applications, service capabilities, and digital solutions. The AVS segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The PCS segment specializes in providing medical devices, consumables, services, and digital solutions. The PDx segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded in 1892. It was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare Technologies Inc

Bearish Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$VTRS" data-symbol-id="VTRS" href="https://stocktwits.com/symbol/VTRS" target="_blank">Viatris</a> agreed on Thursday to buy Pacira BioSciences for $1.65 billion in cash, or $36.50 a share.</li><li>GE HealthCare agreed to pay $945 million in cash for Sofie Biosciences, a private U.S. firm that makes radioactive tracers for PET scans.</li><li>Biohaven licensed Asian rights to its antibody-clearing drugs to Japan’s Ono Pharmaceutical; Alector signed a separate license with Genentech.</li></ul><p>U.S.-listed drugmakers spent the week selling rights or buying products they can already sell. Cash went to approved pain drugs, a factory that makes imaging agents, and two license deals, including one that leaves the American company in charge of its home market.</p><p>The companies did not purchase experimental drug candidates as they did last week when drugmakers, including Novo Nordisk and Novartis, invested in experimental drugs.</p><h2 class="st-heading-2">Viatris Buys A Pain Franchise</h2><p>Viatris (VTRS) agreed on Thursday to buy Pacira BioSciences (PCRX) for $1.65 billion in cash, or $36.50 a share. That was a premium of about 45% to Pacira’s last close.</p><p>Pacira sells Exparel, a long-acting numbing shot used after surgery, and Zilretta, an injection for knee arthritis. Pacira expects Exparel sales of $600 million to $620 million this year. Viatris, which is waiting on a U.S. decision for its own non-opioid pain drug, said the products fit its push into branded medicines and that it would try to sell them in more countries. The deal is expected to close by the end of 2026. Pacira shares closed Thursday at $36.39, up 44%.</p><h2 class="st-heading-2">GE Healthcare Buys The Delivery Network</h2><p>GE HealthCare (GEHC) agreed to pay $945 million in cash for Sofie Biosciences, a private U.S. firm that makes radioactive tracers for PET scans. Sofie runs 15 manufacturing sites and 21 cyclotrons. The tracers fade within hours, so the plant has to be near the hospital. GE also gets U.S. rights to FAPI-74, an experimental cancer-imaging agent it already controls outside the country. Sofie already makes GE’s heart-scan product Flyrcado. Closing is expected in the first half of 2027.</p><h2 class="st-heading-2">Two Biotechs License Out</h2><p>Biohaven (BHVN) licensed Asian rights to its antibody-clearing drugs to Japan’s Ono Pharmaceutical. The package is $80 million at signing and a further $20 million expected within about a year, plus royalties of roughly 20 percent on Ono’s sales in Japan and other Asian markets. Biohaven keeps the United States, Europe, and China. The lead drug, BHV-1300, is in a late-stage study for Graves’ disease.</p><p>Alector (ALEC) signed a separate license with Genentech, the U.S. unit of Roche (RHHBY). Alector gets $100 million upfront and could receive up to $1.17 billion more for AL-050, an experimental enzyme therapy aimed at Parkinson’s and other brain disorders. Genentech gained worldwide rights to develop the AL-050 program. The deal lands three months after GSK (GSK) walked away from an older Alector partnership.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around VTRS and PCRX &nbsp;was in 'bullish' territory over the past 24 hours, while GEHC and BHVN stayed within the 'neutral' territory. Sentiment around ALEC stayed within the 'extremely bullish' territory.</p><p>While VTRS has gained 42% year-to-date, PCRX has added 40%, BHVN 7%, and ALEC 33%. Meanwhile, GEHC has fallen 20%.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-sets-new-52-week-high-as-nasdaq-100-reentry-meets-nih-cancer-vaccine-push/cZxGGuoRBnj">MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com</p>

Assortment of multi-colored pills, tablets, and capsules scattering on a vibrant blue surface representing healthcare and medicine. Source: Getty Images

Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents. 

Alector Inc

Biohaven Pharmaceutical Holding Company Ltd

Pacira BioSciences Inc

Viatris Inc

Track GEHC stock price, charts, news and real-time market activity on Stocktwits. Join the GEHC message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around GE HealthCare Technologies Inc stock.

GEHC Stock Price Today - GE HealthCare News, Charts, Retail Sentiment

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$69.76
Prev Close	$69.57
Open	$69.29
Dividend Yield	0.17%
50-Day Moving Average	$68.55
Beta	1.14
Avg. Volume	3.58M
PE Ratio	16.03

52-Week High	$89.77
52-Week Low	$58.75
Market Capitalization	$31.42B
EPS (Annual)	$4.55
Price to Book	2.87
Revenue Per Employee	$381,944.44

Feed

News

Sentiment

Earnings

Fundamentals

Info

GEHC Fundamentals